louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05182619: Stellate Block Versus Nimodipine Infusion for Traumatic Brain Injury
Official title: Ultrasound-guided Stellate Ganglion Block Versus Nimodipine Infusion for Enhancement of Cerebral Blood Flow in Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Traumatic Brain Injury
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2022-01-10
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the study is designed to perform an intervention for enhancement of cerebral blood flow in patients with traumatic brain injury showing vasospasm through transcranial doppler


Eligibility criteria: Inclusion Criteria:

* patients more than 18 ys old with isolated head trauma and traumatic brain injury

Exclusion Criteria:

* • Hemodynamic instability (mean ABP less than 70 mmHg)

  * History of severe systemic disease including cardiopulmonary failure or hepatorenal failure
  * Allergy to local anesthetics
  * Coagulation disorders
  * Abnormal neck structures disturbing normal anatomy as neck tumors

Primary outcomes:
measure: enhancement of cerebral blood flow
timeFrame: one week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06879119: Clinical Evaluation of Localized Scalp Thread Embedding for Male Androgenetic Alopecia
Official title: Clinical Efficacy Study of Localized Scalp Thread Embedding in the Treatment of Male Androgenetic Alopecia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Androgenetic Alopecia
Keywords: Androgenetic Alopecia
Interventional study
Non-pharmacological interventions
Lead sponsor: Beijing University of Chinese Medicine, Shenzhen Hospital
Sponsor class: OTHER
First posted: 2025-03-17
Enrollment: 9
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This clinical study aims to evaluate a breakthrough treatment for hair loss (androgenetic alopecia, AGA) using dissolvable threads placed under the scalp skin. The investigators hypothesize that these specially designed threads can improve hair growth, avoiding the need for invasive surgery.

Current AGA treatments taken orally often have limitations, prompting researchers to explore localized approaches. While early studies show promise for localized scalp thread embedding, three key challenges remain: 1) No standardized way to measure effectiveness, 2) Lack of objective biological markers to track progress, and 3) Limited understanding of how exactly these treatments work.

This study addresses these gaps through precise thread placement in balding areas, following international dermatology guidelines. Using advanced measurement tools, the investigators will track changes in hair thickness (primary measure), blood flow patterns under the skin, and oil gland activity (secondary measures). By focusing on one key treatment factor, this research provides the first comprehensive evidence showing how this minimally invasive approach may slow or reverse AGA progression.


Eligibility criteria: Inclusion Criteria:

* Male sex
* Age 18-50 years
* No clinically significant comorbidities
* Androgenetic alopecia (Hamilton-Norwood III-V)
* No systemic anti-hair loss therapy use within 3 months
* No topical hair regrowth agent use within 3 months

Exclusion Criteria:

* Active scalp infection
* Scalp psoriasis
* Scalp eczema
* Open scalp wounds
* Allergy to thread materials
* Uncontrolled diabetes mellitus
* Immunodeficiency disorders
* Non-compliance with follow-up visits
* Refusal to provide informed consent
* Investigator-deemed contraindications

Primary outcomes:
measure: Hair Shaft Parameters
timeFrame: From enrollment to the end of treatment at 6 months
Secondary outcomes:
measure: Scalp thickness
timeFrame: From enrollment to the end of treatment at 6 months
measure: Scalp blood flow
timeFrame: From enrollment to the end of treatment at 6 months
measure: Scalp sebum production
timeFrame: From enrollment to the end of treatment at 6 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Dongfang Hospital Beijing University of Chinese Medicine
state: Beijing
Study officials:
References:
Clinical trial NCT06620419: Clinical Study of External Electrical Stimulation for Male Incontinence
Official title: Clinical Evaluation of Perineal Electrical Stimulation for Urinary Incontinence in Men
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Urinary Incontinence
Keywords: male
men
prostatetectomy
incontinence
electrical stimulation
Lead sponsor: Elidah, Inc.
Sponsor class: INDUSTRY
First posted: 2024-10-01
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Perineal-applied electrical stimulation shaped for males.
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to evaluate the effectiveness of the Elidah neuromuscular stimulation treatment to reduce incontinence in men post-prostatectomy.


Eligibility criteria: Inclusion Criteria:

* Scheduled for robotic-assisted laparoscopic prostatectomy
* Read and speak English
* Predominant SUI of at least 1 pad/day

Exclusion Criteria:

* History or symptoms of urinary incontinence, urinary retention, extra-urethral incontinence, overflow incontinence
* Complete denervation of the pelvic floor
* Severe Obesity as defined by BMI \&gt;= 40
* Has undergone pre-op pelvic floor exercise strengthening
* Pelvic pain/painful bladder syndrome
* Implanted cardiac device, untreated cardiac arrhythmia or suffer from other heart problems.
* History of epilepsy
* Underlying neurologic/neuromuscular disorder
* Metal implants in the abdomen or pelvic area
* Chronic coughing
* Impaired decision making, suicidal thoughts, or drug/alcohol dependence
* Uncontrolled intercurrent illness that would limit compliance with study requirements
* Lacks capacity to adhere with study requirements
* Lacks capacity to consent for themselves.

Primary outcomes:
measure: Reduction in Leakage by Pad weight
timeFrame: 6 weeks
Secondary outcomes:
measure: Safety measured by no Adverse events
timeFrame: 6 weeks
measure: Quality of Life Improvement
timeFrame: 6 weeks
measure: Quality of Life Improvement
timeFrame: 6 weeks
measure: Reduction in leakage
timeFrame: 6 weeks
measure: Reduction in leakage at Night
timeFrame: 6 weeks
measure: Reduction in leakage
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Monroe
country: United States
facility: Elidah
state: Connecticut
Study officials:
affiliation: Elidah, Inc.
name: Gloria Kolb, MS,MBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01247441: Breast Cancer Registry - National University Health System, Singapore
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Cancer
Keywords: All breast cancer patients who were diagnosed or managed in NUH will be included into this registry
Lead sponsor: National University Hospital, Singapore
Sponsor class: OTHER
First posted: 2010-11-24
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Breast Cancer

Brief summary: The Breast Cancer Registry aims to collect clinical data of all breast cancer patients diagnosed and/or treated in the National University Hospital, with the goal of understanding risk factors, presenting symptoms, diagnosis, treatment, and outcome data of breast cancer in Singapore. This information will contribute to improving management of breast cancer patients.


Eligibility criteria: Inclusion Criteria:

- All breast cancer patients who were diagnosed or managed in NUH.

Exclusion Criteria:

- Non breast cancer patients.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National University Hospital
Study officials:
References:
citation: Dabakuyo TS, Bonnetain F, Roignot P, Poillot ML, Chaplain G, Altwegg T, Hedelin G, Arveux P. Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival. Ann Oncol. 2008 Feb;19(2):276-83. doi: 10.1093/annonc/mdm491. Epub 2007 Oct 24.
citation: Park YH, Kim ST, Cho EY, Choi YL, Ok ON, Baek HJ, Lee JE, Nam SJ, Yang JH, Park W, Choi DH, Huh SJ, Ahn JS, Im YH. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat. 2010 Feb;119(3):653-61. doi: 10.1007/s10549-009-0665-x.
Clinical trial NCT02973841: Sono-ease Device for Internal Jaguar Vein Cannulation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Internal Jugular Vein Cannulation
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2016-11-25
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A novel device attached to ultrasound probe designed to increase success rate and safety of internal jugular vein cannulation.


Eligibility criteria: Inclusion Criteria:

* all patients indicated for IJV catheterization

Exclusion Criteria:

* neck deformities-coagulopathy

Primary outcomes:
measure: complications rate
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00765141: A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host Microbe Scientific Study
Official title: A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host Microbe Scientific Study
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Infection
Keywords: wound debridement
removed orthopedic implants
removed catheters or shunts
excised tonsils
amputated tissue
sputum, stool
or other excretions.
Lead sponsor: Southwest Regional Wound Care Center
Sponsor class: OTHER
First posted: 2008-10-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The samples can include material such as wound debridement, removed orthopedic implants, removed catheters or shunts, excised tonsils, amputated tissue, sputum, stool, or other excretions.

Brief summary: The intent of this protocol is to salvage human-related material that is normally destined for destruction, so it can be used in infection-related scientific studies.

Detailed description: This clinical material can be studied in order to better understand the molecular, cellular, or ecological components of the infected or potentially infected tissue or device. These studies may be able to provide important insights into the keys of chronic infections, complex infections, medical biofilms, pathogen ecology, and healing.

Eligibility criteria: Inclusion Criteria:

* The Subject must be 18 years of age or older.
* The Subject must be mentally competent as determined by the Investigator.

Exclusion Criteria:

* The Subject may not be currently incarcerated.
* The Subject may not be knowingly pregnant.
* The Subject may not be institutionalized.
* The Subject may not be an employee or student of the investigator or sponsor.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Lubbock
country: United States
facility: Southwest Regional Wound Care Center
state: Texas
Study officials:
affiliation: Southwest Regional Wound Care Center
name: Randall Wolcott, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01893541: PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?
Official title: PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: CIRRHOSIS
ESOPHAGEAL VARICES
Keywords: CIRRHOTIC
VARICEAL BLEEDING
PRIMARY PROPHYLAXIS
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
First posted: 2013-07-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 78
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This prospective randomized controlled trial will compare endoscopic band ligation (EBL) with propranolol and EBL alone in primary prophylaxis of variceal bleeding among cirrhotic patients with high-risk varices.

Detailed description: BACKGROUND AND AIMS

Bleeding from esophagogastric varices (EV) is a major complication of portal hypertension. Beta-blockers are a well-established cornerstone of portal hypertension treatment. Band ligation is the best endoscopic treatment to prevent EV bleeding. The exact benefit of beta-blocker association to band ligation remains to be defined, especially for primary prophylaxis. This prospective randomized controlled trial will compare EBL with propranolol and EBL alone in primary prophylaxis of variceal bleeding among cirrhotic patients with high-risk varices. PATIENTS AND METHODS: The patients with high-risk varices will be randomly allocated to EBL plus propranolol (Group I) or EBL alone (Group II). EBL will be performed at 3-week interval till obliteration of varices. In Group I, incremental dosage of propranolol (sufficient to reduce heart rate to 55 beats/min or 25% reduction from baseline) will be administered and will be continued after obliteration of varices until the end of the study. The follow-up of patients will be 2 years. The primary outcome of this study will be EV recurrence during two years of follow-up. The secondary outcomes will be EV eradication, bleeding before eradication, mortality and complications during the same follow-up.

Eligibility criteria: Inclusion Criteria:

* Liver cirrhosis with esophageal varices
* Age between 18 and 78 years
* Accept to participate

Exclusion Criteria:

* Portal hypertension by schistosomiasis
* Contraindications for propranolol use
* Do not accept to participate

Primary outcomes:
measure: The primary outcome of this study will be esophageal varices recurrence
timeFrame: Two years
Secondary outcomes:
measure: The secondary outcomes of this study will be variceal eradication, bleeding before eradication, mortality and complications.
timeFrame: two years
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Federal University of São Paulo
Study officials:
affiliation: Federal University of São Paulo
name: Danielle Q Bonilha, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00980941: Types of Starch and Their Effect on Blood Glucose, Appetite and Food Intake
Official title: The Effect of Different Types of Starch on Glycemic Response, Subjective Appetite and Short-term Food Intake in Young Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity Prevention
Diabetes Prevention
Keywords: starch
carbohydrates
blood glucose
food intake
satiety
appetite
Lead sponsor: University of Toronto
Sponsor class: OTHER
Collaborators: name: Ingredion Incorporated
First posted: 2009-09-21
Enrollment: 17
Sex: MALE
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The investigators hypothesize that different types of starch vary in their effects on appetite, blood sugar and food intake. In this study, subjects consumed five soups containing 50 g of whole grain, high amylose corn, regular corn or maltodextrin starches or no added starch at one week intervals. The investigators measured food intake at 30 minutes, appetite and blood sugar.


Eligibility criteria: Inclusion Criteria:

* Healthy males with a BMI of 20-24.9 kg/m2

Exclusion Criteria:

* Females
* Smokers
* Breakfast skippers
* Individuals with diabetes or other metabolic diseases

Primary outcomes:
measure: Blood glucose
timeFrame: 0-170 min
measure: Food intake
timeFrame: at 30 min after the treatment
measure: Appetite
timeFrame: 0-170 min
Secondary outcomes:
measure: Water intake
timeFrame: at 30 min
measure: Palatability of treatments
timeFrame: 0-170 min
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Department of Nutritional Studies, University of Toronto
state: Ontario
Study officials:
affiliation: University of Toronto
name: Harvey Anderson, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Anderson GH, Cho CE, Akhavan T, Mollard RC, Luhovyy BL, Finocchiaro ET. Relation between estimates of cornstarch digestibility by the Englyst in vitro method and glycemic response, subjective appetite, and short-term food intake in young men. Am J Clin Nutr. 2010 Apr;91(4):932-9. doi: 10.3945/ajcn.2009.28443. Epub 2010 Feb 17.
Clinical trial NCT02776241: Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
Official title: Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney: The HYDRA Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: ADPKD
Keywords: ADPKD
total kidney volume
kidney disease
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
First posted: 2016-05-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The objective of this study is to measure the influence of both short term water restriction and high water intake on total kidney volume, measured by Magnetic Resonance Imaging (MRI) scan in Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients.

Detailed description: Patients will be randomized to either water restriction for 3 hours or high water intake (20 ml/kg) for 1 hour. Before intervention and after intervention patients will have an MRI scan of the kidneys to measure the total kidney volume (TKV) (differentiated in cortex, medulla and cyst volume). The objective is to identify whether water restriction or high water load will change the TKV. Secondly investigators will analyze different biomarkers (aldosterone, renin, vasopressin/copeptin, urine- and blood-osmolarity) before and after the intervention.

Eligibility criteria: Inclusion Criteria:

* ADPKD
* CKD stage 1-3

Exclusion Criteria:

* Patients treated with diuretics
* Pregnancy
* Change in antihypertensive treatment \< 1 month
* Any condition contraindicating MR scan

Primary outcomes:
measure: Change in total kidney volume
timeFrame: Baseline and 3 hours
Secondary outcomes:
measure: Change in total cyst volume
timeFrame: Baseline and 3 hours
measure: Change in plasma renin
timeFrame: Baseline and 3 hours
measure: Change in plasma aldosterone
timeFrame: Baseline and 3 hours
measure: Change in plasma copeptin
timeFrame: Baseline and 3 hours
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet
Study officials:
affiliation: Rigshospitalet, Denmark
name: Signe V Naver, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06710041: Kinesiotaping in Carpal Tunnel Syndrome
Official title: Effects of Kinesiotaping in Carpal Tunnel Syndrome Treatment: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carpal Tunnel Syndrome (CTS)
Keywords: carpal tunnel syndrome
Kinesiotaping
Sham taping
Lead sponsor: Karadeniz Technical University
Sponsor class: OTHER
First posted: 2024-11-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective: Kinesiotaping (KT) is a relatively new technique, which reduces the pressure on the median nerve by extending the transverse carpal ligament. The aim of this study was to evaluate the effectiveness of KT on Carpal tunnel syndrome (CTS) in a randomized, placebo-controlled manner.

Methods: Patients were randomly divided into three groups: Group 1 (KT plus tendon and nerve gliding exercises), Group 2 (sham-taping plus exercises) and Group 3 (exercises alone, control group). KT was applied 3 times with 5-day intervals throughout the study, with "neural technique" for median and ulnar nerves and "area correction technique" for carpal tunnel releasing. In the placebo group kinesiotapes were applied without stretching and proper position. Hand grip strength, VAS, Boston Carpal Tunnel Syndrome Questionnaire (BCTQ), and Short Form-12 (SF-12) were measured as outcome parameters at the first visit, 3rd and 6th week.


Eligibility criteria: Inclusion Criteria:

* clicical diagnosis of mild and moderate CTS
* having the CTS symptoms for at least 6 weeks

Exclusion Criteria:

* electrophysiological diagnosis of severe CTS,
* thenar atrophy,
* local corticosteroid injection or KT application or physical therapy treatment for CTS within the last 3 months,
* patients with secondary metabolic causes for CTS (such as diabetes mellitus, pregnancy, rheumatoid arthritis, sarcoidosis, thyroid disease),
* patients with other conditions that may cause neck and arm pain (cervical disc hernia, arthritis, epicondylitis, rotator cuff syndrome),
* a history of fracture in the wrist,
* previous CTS surgery.

Primary outcomes:
measure: pain level
timeFrame: From enrollment to the end of treatment at 3 weeks
Secondary outcomes:
measure: Boston Carpal Tunnel Syndrome Questionnaire (BCTQ)
timeFrame: From enrollment to the end of treatment at 6 weeks
Other outcomes:
Locations:
city: Trabzon
country: Turkey
facility: Karadeniz Technical University
Study officials:
References:
citation: Geler Kulcu D, Bursali C, Aktas I, Bozkurt Alp S, Unlu Ozkan F, Akpinar P. Kinesiotaping as an alternative treatment method for carpal tunnel syndrome. Turk J Med Sci. 2016 Jun 23;46(4):1042-9. doi: 10.3906/sag-1503-4.
citation: Giray E, Karali-Bingul D, Akyuz G. The Effectiveness of Kinesiotaping, Sham Taping or Exercises Only in Lateral Epicondylitis Treatment: A Randomized Controlled Study. PM R. 2019 Jul;11(7):681-693. doi: 10.1002/pmrj.12067. Epub 2019 Mar 28.